Development of commercially viable enantioselective processes for HIV-1 NNRTIs

R L Parsons1

  • 1DuPont Pharmaceuticals, Chemical Process Research and Development, Chambers Works, PRF-112, Deepwater, NJ 08023, USA. rodney.l.parsons@dupontpharma.com

Current Opinion in Drug Discovery & Development
|August 4, 2009
PubMed